Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MK-2206 in Relapsed/Refractory AML
NCT01253447Phase 2Completed
- Sponsor
- National Cancer Institute
- Start
- Oct 2010
- Primary completion
- Oct 2013
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of MK-2206 in acute myeloid leukemia (AML), sponsored by National Cancer Institute. Started Oct 2010; status: completed.
02
Drugs
MK-2206
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT01253447.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01253447.